The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

The US FDA has ordered BioNTech to immediately halt its Phase I/II trial of BNT165e, a malaria vaccine candidate, pending ...

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...

Amgen and AstraZeneca have reported outcomes from the WAYPOINT trial of Tezspire for treating chronic rhinosinusitis with ...

AstraZeneca has reported positive “high-level” outcomes from the Phase III MATTERHORN trial of Imfinzi (durvalumab) with FLOT chemotherapy.

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial.

Subjects in the fourth cohort will receive a dose nearly 50% higher than the previous cohort. Credit: Amnaj Khetsamtip/Shutterstock. The Safety Review Committee (SRC) has granted unanimous approval ...

Merck & Co (MSD) is looking to file for approval of its human immunodeficiency virus (HIV) treatment after two positive Phase III trial readouts. Its once-daily oral combination of the approved drug ...

Overall survival data was not yet mature with less than a quarter of the required number of events having occurred. Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human ...